We also demonstrated that the immune-related pathways in tumor tissues of ER/PR-negative patients were significantly activated, which is bioinformatically consistent with the acknowledgment that HR-positive BRCA tends to have fewer immune infiltrates and be more immunogenic than HR-negative microenvironment (51–53). The gene discussed is ESR1; the disease is neoplasm.